MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research to evaluate many intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Most important demo targets were To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when one of several exp... https://jakeo999huf3.elbloglibre.com/profile